{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"acute myeloid leukemia undergoing intensive treatment","name":"ODYSSEE","nct_id":"NCT02928523","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=odyssee-nct02928523. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ODYSSEE","arms":[{"description":"Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.","label":"Autologous Fecal Microbiota Transplantation","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2018-06-20","type":"ACTUAL"},"conditions":["Leukemia, Myeloid, Acute"],"enrollment":{"count":20,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Autologous Fecal Microbiota Transplantation","otherNames":["MaaT011"],"type":"DRUG"}],"last_update":"2020-09-09","lead_sponsor":"MaaT Pharma","official_title":"PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2017-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Evaluation of AFMT efficacy in dysbiosis correction by measure of microbiota diversity","timeFrame":"40 days"},{"measure":"Evaluation of AFMT efficacy in MDRB eradication based on bacterial culture","timeFrame":"40 days"}],"references":[{"citation":"Malard F, Vekhoff A, Lapusan S, Isnard F, D'incan-Corda E, Rey J, Saillard C, Thomas X, Ducastelle-Lepretre S, Paubelle E, Larcher MV, Rocher C, Recher C, Tavitian S, Bertoli S, Michallet AS, Gilis L, Peterlin P, Chevallier P, Nguyen S, Plantamura E, Boucinha L, Gasc C, Michallet M, Dore J, Legrand O, Mohty M. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6.","pmid":"34035290","type":"DERIVED"}],"start_date":{"date":"2016-06"},"study_type":"INTERVENTIONAL","title":"PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients","url":"https://clinicaltrials.gov/study/NCT02928523"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/odyssee-nct02928523"}